Acerta Pharma
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Acerta Pharma sits in the top decile of US sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count).
Acerta Pharma: 38 sponsored US clinical trials, none currently recruiting.
Acerta Pharma sponsors 38 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 22 completed. 6 of these trials are in Phase 3-4 (later-stage) and 32 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Lymphocytic Leukemia, with 7 trials.
Top-decile sponsor footprint
Acerta Pharma ranks in the top decile of sponsors by registered trial count (#448 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
38 total, page 1 of 1
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970318
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
NCT02717624
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
NCT02586857
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
NCT02213926
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
NCT02180711
An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia
NCT02180724
Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia
NCT02157324
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
NCT02029443
A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants
NCT05140096
Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
NCT03968848
Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)
NCT03527147
A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies
NCT03205046
A Study to Evaluate the Effect of Gastric pH on Acalabrutinib Pharmacokinetics (PK) in Healthy Adult Participants
NCT04905043
A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants
NCT04867980
A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants
NCT04898101
A Study to Evaluate the Effect of an Acidic Formulation of Acalabrutinib (ACP-196), Acidic Beverage, or Grapefruit Juice on the Pharmacokinetics (PK) of ACP-196 Alone and Coadministered With Omeprazole
NCT04876807
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
NCT02537444
Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer
NCT02570711
Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma
NCT02454179
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
NCT02362048
Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer
NCT02448303
ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate
NCT02387762
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
NCT02351739
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
NCT02362035
An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma
NCT02211014
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
NCT02337829
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
NCT02296918
Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies
NCT02328014
A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196
NCT04867941
A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196
NCT04914936
Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma
NCT02112526
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants
NCT04901923
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 11 |
| Phase 3 | 6 |
Therapeutic Areas
How the Acerta Pharma early-phase archive is shaped
38 indexed studies, none listed as recruiting (0% open); 22 completed (58%).
Phase mix: 6 late (III/IV) vs 32 early (I/II) (early-phase heavy).
Top condition: Chronic Lymphocytic Leukemia (7 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Acerta Pharma: archived-pipeline peers nationwide
Peers matched on 38 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Acerta Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 38 archived trials
- Astex Pharmaceuticals · 38 trials · 0% recruiting
- Corewell Health West · 38 trials · 11% recruiting
- DePuy Orthopaedics · 38 trials · 5% recruiting
- Ethicon · 38 trials · 11% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Acerta Pharma page
38 registered trials is a research-attention snapshot, not an endorsement of Acerta Pharma or any single study.
- None of Acerta Pharma's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Chronic Lymphocytic Leukemia is the condition Acerta Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Lymphocytic Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Acerta Pharma pipeline card: 38 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.